{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-25-000112","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.673492+00:00","generated_at":"2026-05-17T20:30:44.666794+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmunityBio Q2 revenue jumps 60% to $26.4M; net loss narrows to $92.6M","bullets":["Q2 product revenue $26.4M, up 60% from Q1 and from $990k in Q2 2024; YTD sales $42.9M.","Net loss $92.6M ($0.10/share) vs $134.6M in Q2 2024; operating loss narrowed.","Cash $153.7M at June 30; $80M equity financing closed July 2025 with potential $96M warrant proceeds.","UK MHRA approved ANKTIVA for BCG-unresponsive NMIBC; FDA refused to file sBLA for papillary-only NMIBC, company re-evaluating.","ANKTIVA unit volume grew 246% in 1H 2025 vs 2H 2024 since J-code approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-25-000112","json":"https://secwatch.observer/filing/0001326110-25-000112.json","markdown":"https://secwatch.observer/filing/0001326110-25-000112.md","text":"https://secwatch.observer/filing/0001326110-25-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000112/0001326110-25-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000112/ibrx-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:30:44.666794+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}